Technology

Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology

Published

1 year ago

February 24, 2025

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform

Built on Illumina’s powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability

SAN DIEGO, Feb. 24, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry’s largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina’s powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio will be presented today at the Advances in Genome Biology and Technology (AGBT) General Meeting.

“Illumina is the backbone of innovation for our industry, and we’re bringing disruptive, new solutions at a scale that only Illumina can deliver,” said Jacob Thaysen, CEO of Illumina. “Illumina has paved the way for genomic breakthroughs, and now we are committed to accelerating advances on all frontiers of multiomics. Our technologies will help researchers gain a more complete understanding of biology, accelerating the translation of data into insights that can truly unlock precision health care.”

“Illumina is doing what we do best: breaking new ground and setting the standard,” said Steve Barnard, PhD, chief technology officer of Illumina. “Just as researchers have come to rely on an accurate, complete and comprehensive view of the genome, Illumina is now bringing the same attributes to the entire range of multiomics exploration, with the complete workflows needed to ensure value and usability. These solutions represent a leap forward in discovery, and we can’t wait to bring these solutions into more labs.”

Illumina’s announcements at AGBT drive new scale, quality in multiomic discovery

Illumina’s AGBT Gold Sponsor Workshop today will showcase the latest advances across a range of multiomic capabilities enabled on Illumina’s sequencing platforms and supported by its new multimodal data analysis platform. The updates illustrate Illumina’s continued commitment to provide customers with end-to-end solutions that streamline and simplify workflows, and its growing portfolio of multiomics offerings, which includes Illumina Single Cell and Illumina Protein Prep.

Constellation mapped reads unlocks new possibilities in rare disease detection. Illumina’s constellation mapped reads technology is designed to deepen understanding of the genome and streamline whole-genome workflows while eliminating traditional library prep. The technology is currently in development, and early testing demonstrates enhanced mapping of challenging genomic regions, ultra-long phasing, and improved detection of large structural rearrangements. These advances show promise to support faster and more comprehensive detection of disease.

Stephen Kingsmore, MD, DSc, president and CEO of Rady Children’s Institute for Genomic Medicine, will share his experience with constellation mapped read technology and the potential impact for comprehensive, rapid WGS that can enable earlier diagnosis of genetic and rare diseases.

“Constellation’s ability to provide a high-resolution view of structural variation — including the most common cause of hemophilia A in boys, which was impossible with standard methods — is an impressive advance in genome sequencing,” said Kingsmore. “Previously these variants had to be identified by custom one-off assays that typically took a month or more. Constellation makes it possible to go from rapid sequencing to insights in just over a day.”

Kingsmore will also present an abstract in a concurrent session, “A novel WGS workflow to aid in the design of allele-specific antisense oligonucleotides for patients with rare genetic conditions,” on Monday, February 24, 4:30–4:50 p.m. ET. Products based on constellation mapped reads technology are expected to be commercially available in 2026.

Illumina unveils a single-cell solution for CRISPR research. Single-cell technology has the potential to uncover critical biological insight across a broad range of research fields, including oncology, immunology, and drug target discovery. The company’s new Perturb-seq solution brings new capabilities into Illumina’s multiomics portfolio at unprecedented scale for Perturb-seq experiments, enabling discovery of mechanism of action for drugs and clinical research on therapeutic treatments for complex genetic diseases at the single-cell level. This technology will also be used in a collaboration announced last week with Broad Clinical Labs, aimed at rapidly scaling single-cell solutions and enabling a 5 billion single-cell atlas ecosystem within three years.

The solution is expected to launch by the end of 2025 with three new kit formats that are compatible with 10,000, 100,000, and 1 million cells per sample, facilitating targeted studies with 100 guide RNA (gRNA) sequences to full genome-scale discovery with over 10,000 gRNAs per experiment. The solution leverages new improvements on the foundational Fluent PIPseq technology for dual measurement of CRISPR gRNA sequences and 3′ RNA gene expression in the same assay. The gRNA direct capture provides a more cost-effective workflow, improved sensitivity, and higher scalability than current single-cell kits.

The solution will provide single-cell readout of CRISPR activation, inactivation, or targeted gene editing Perturb-seq experiments for exciting applications, including cell atlasing or drug screening research. The kits are compatible across Illumina sequencers, and the workflow includes DRAGEN Single Cell RNA Analysis for CRISPR gRNA screening through Illumina software.

Illumina’s 5-base solution for methylation analysis and variant calling powers accuracy of genetic and epigenetic data. Currently in early access, Illumina’s 5-base solution for methylation analysis enables simultaneous genetic variant and methylation detection in a single assay. DNA methylation impacts how and when genes are expressed. The ability to detect and analyze DNA methylation can improve researchers’ understanding of how DNA methylation patterns influence biological processes like development, cell differentiation, tumor progression, and environmental exposures. Ultimately, it can help researchers identify potential biomarkers for detection, diagnosis, and treatment strategies.

Planned for launch in 2026, Illumina’s solution will provide 5-base insights into the genome, cell-free DNA, or targeted assays through a single library preparation, sequencing, and analysis run, enabling deeper understanding of the genome while remaining cost effective. Currently, industry barriers to adoption of 5-base solutions include cost, usability, and lack of reliable analytics solutions. Existing offerings for simultaneous DNA and methylation detection are limited in the accuracy they can achieve for both genetic and epigenetic data. Illumina’s solution aims to address these barriers by delivering the easiest, most cost effective end-to-end solution for high-accuracy detection of both genetic variants and methylation in a single assay.

Early access customer data will be presented by Bekim Sadikovic, PhD, director of the Molecular Genetics Laboratory at London Health Sciences Centre Research Institute, in a concurrent session on Tuesday, February 25, 9:10–9:30 p.m. ET, titled, “Novel integrated platform for simultaneous detection of genetic variants and epigenetic signatures in rare undiagnosed genetic diseases.”

Illumina brings spatial transcriptomics to scale. Announced last week, Illumina will also showcase its new spatial transcriptomics technology, which delivers cellular resolution across millions of cells per slide, driving new avenues for research and discovery. Because it is powered by Illumina sequencers and integrated multimodal analysis software, Illumina’s spatial technology delivers a scale in whole transcriptome research that has never before been possible. The technology boasts a capture area nine times larger than existing technologies, and with four times greater resolution. The Broad Institute and Illumina will collaborate on a groundbreaking Spatial Flagship Project, leveraging Illumina’s new spatial technology to demonstrate the transformative potential of large-scale spatial datasets.

Spatial transcriptomics allows researchers to explore biological interactions at the cellular level. For instance, through “cell atlasing,” which maps the detailed arrangement of cells, researchers can gain novel insights into complex tissue structures that affect disease. Illumina’s spatial technology will fuel life sciences breakthroughs ranging from tumor microenvironments to disease pathways, neurobiology, immuno-oncology, and more. As a complete end-to-end solution, it will also deliver the highest value for single-cell and spatial researchers at a more affordable price point. Commercial launch of the technology is planned for 2026.

Illumina Connected Multiomics (ICM) delivers Illumina’s first fully integrated multimodal analysis software. Offering seamless sample-to-insights workflows, ICM is a multiomics analysis solution that helps researchers explore and analyze multimodal data sets, unlocking deeper biological insights. It’s a simple, intuitive tool that any scientist – even without a bioinformatics background – can use to generate powerful statistics and interactive visualizations. This comprehensive analytics platform replaces the need for various open-source tools, which can be difficult and time-consuming to set up and maintain. ICM will deliver the reliable, accurate, and integrated insights needed to overcome barriers to breakthroughs from layers of omic data.

The company’s Gold Sponsor Workshop at AGBT will be held February 24, 12–1:30 p.m. ET. Illumina will demonstrate its end-to-end workflows throughout the AGBT conference in Osprey Lounge 1. To learn more about Illumina’s multiomic solutions, visit illumina.com/innovation.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Salli Schwartz
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-transforms-multiomic-research-with-new-technologies-to-unlock-deeper-understanding-of-biology-302383424.html

SOURCE Illumina, Inc.

Technology

Meridian Singapore Immigration Launches New Website to Simplify the PR Application Journey for Foreigners in Singapore

Published

2 hours ago

April 30, 2026

New online platform provides clear, structured guidance for Employment Pass and S Pass holders navigating Singapore’s residency and Permanent Residency pathways

SINGAPORE, April 30, 2026 /PRNewswire/ — Meridian Singapore Immigration Pte. Ltd. has officially launched its new website at meridianimmigration.sg, a resource built specifically for foreigners living and working in Singapore who are exploring Permanent Residency or long-term residency options.

The platform arrives at a time when Singapore’s expatriate and foreign professional community is growing rapidly, yet many EP and S Pass holders report struggling to find clear, reliable information on the PR application process. Singapore’s immigration framework is among the most structured in Southeast Asia, with eligibility criteria, documentation requirements, and submission windows that change frequently. For individuals navigating this process without professional guidance, the stakes are high and the margin for error is narrow.

Meridian’s website was built to address that gap directly. The platform offers detailed explanations of available immigration pathways, structured consultation options, and educational resources developed by the firm’s team of immigration specialists. Rather than presenting a services catalogue, the site walks users through the considerations relevant to their specific situation, whether they hold an Employment Pass, S Pass, or are planning for their family’s long-term residency in Singapore.

“We built this platform because we saw how overwhelming and confusing the immigration process can be for people who genuinely want to build their lives here,” said a spokesperson for Meridian Singapore Immigration. “Our goal is to be the trusted partner that walks them through every step with clarity and integrity.”

Singapore’s continued attractiveness as a regional hub for multinational corporations, financial institutions, and technology firms means the pipeline of foreigners seeking long-term residency options remains substantial. At the same time, the ICA’s PR application framework has grown more nuanced, with factors such as economic contributions, family ties, and community integration weighed during assessment. Applicants who proceed without a clear understanding of these criteria often submit applications that are either premature or structurally incomplete.

Meridian’s approach centres on preparation and transparency, helping applicants understand where they stand before they apply and what supporting documentation strengthens their case.

Meridian Singapore Immigration Pte. Ltd. is a professional immigration consultancy dedicated to guiding individuals and families through Singapore’s immigration process. Specialising in Permanent Residency (PR) applications, residency pathways, and compliance support, Meridian offers clear, structured solutions tailored to each client’s unique circumstances. Founded on the values of Guidance, Integrity, and Success, Meridian is committed to making immigration simple, transparent, and accessible for everyone. For more information, visit meridianimmigration.sg or contact info@meridianimmigration.sg / +65 8873 1113.

View original content:https://www.prnewswire.com/apac/news-releases/meridian-singapore-immigration-launches-new-website-to-simplify-the-pr-application-journey-for-foreigners-in-singapore-302757392.html

SOURCE Meridian Singapore Immigration Pte. Ltd.

Technology

Socomec, Daitron team up to meet Japan’s growing power demands

Published

2 hours ago

April 30, 2026

TOKYO, April 30, 2026 /PRNewswire/ — Socomec, a century-old electrical group specialising in mission-critical energy, and Japan’s Daitron, an electronics components distributor, have signed a partnership to deliver power conversion solutions and service backup power and electrical-switching systems across Japan.

The deal combines Socomec’s equipment with Daitron’s on-the-ground engineering team, which has more than 74 years of experience in the Japanese market. The two companies will handle everything from project delivery to ongoing maintenance and spare parts.

The partnership covers three product areas: uninterruptible power supplies (UPS), which keep facilities running during outages; power conversion systems, which ensure the availability and continuity of high-quality energy; and static transfer switches, which automatically reroute power loads between sources without interruption.

Beyond equipment sales, the agreement includes training, spare parts, long-term service contracts and a full range of expert services covering prevention, measurement and analysis, consultancy, deployment and optimisation. Socomec will provide product and technical training to Daitron’s team, while Daitron handles installation, servicing and day-to-day client support in Japan.

The target market spans data centres, semiconductor plants, industrial facilities, hospitals and green buildings, all areas where even brief power interruptions can prove costly. Data center demand in particular is surging, driven by the rapid expansion of artificial intelligence infrastructure, with colocation and enterprise facilities among the primary targets.

“Daitron knows the Japanese market inside and out. They have the people, the relationships, and the hands-on experience, and we bring the technology to match,” said Socomec Asia-Pacific CEO O’Niel Dissanayake. “It’s a natural fit, and together we can offer something neither company could deliver alone.”

“Japan’s data centres, chip factories and industrial plants all require power systems they can count on,” said Masaharu Kato, corporate officer of Daitron. “Socomec’s technology is exactly what these customers need, and our job is to make sure it’s installed, maintained and supported properly. That’s what we do best.”

The partnership comes as Japan faces a step change in power demand. Electricity consumption is expected to grow 5.3% over the next decade, driven by data centres and semiconductor factories, according to the country’s grid operator. Industrial energy demand alone is forecast to rise 18.3% over the same period.

That growth is creating strong demand for reliable power infrastructure. Data centres, for example, run around the clock and cannot afford downtime, making backup power and efficient energy management essential. Socomec’s systems are designed to reduce power consumption without sacrificing reliability, a balance that is becoming increasingly important as operators look to manage both costs and environmental commitments.

Both companies say project planning and bids are already underway, with a long-term goal of expanding the partnership’s reach across Japan as demand grows.

About Daitron

Daitron Co., Ltd. is a Japanese engineering and trading company founded in 1952 and headquartered in Osaka. Listed on the Tokyo Stock Exchange (TYO: 7609), Daitron sells and manufactures electronic components, semiconductor processing equipment and power supply systems. The company has more than seven decades of experience serving Japan’s electronics and manufacturing industries.

SOCOMEC: When energy matters

Founded in 1922, SOCOMEC is an independent industrial group of more than 4,800 experts spread across the world in 30 subsidiaries. Our vocation: design, manufacture and sale of electrical equipment, with a strong expertize in critical power applications. In 2025, SOCOMEC achieved a turnover of 997 million euros (not yet audited).

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/socomec-daitron-team-up-to-meet-japans-growing-power-demands-302755570.html

SOURCE Socomec

Technology

Multi-Destination Travel Surges Across Asia-Pacific This Labour Day, Trip.com Group Data Shows

Published

2 hours ago

April 30, 2026

Multi-city travel across Asia-Pacific grew 35% year-on-yearMulti-city travel outpaces single-destination growth by more than 2xSoutheast Asia sees strong double-digit growth, with Thailand up to 52% YoY

SINGAPORE, April 29, 2026 /CNW/ — Multi-city travel across Asia-Pacific grew 35% year-on-year this Labour Day period, according to data from Trip.com Group. Several Asia-Pacific markets including Japan, South Korea, parts of Southeast Asia and Mainland China celebrate Labour Day, driving strong cross-border and domestic travel flows across the region.

Over 30% of international trips now span multiple destinations, highlighting a continued shift towards more complex, itinerary-led travel. This shift reflects a growing preference to maximise time and value with multiple destinations within a single trip rather than a single location.

Multi-destination trips become a defining travel pattern

While single-destination travel continues to account for most bookings, growth is increasingly driven by more complex itineraries. Multi-destination bookings are growing at more than twice the pace of single-destination travel, reflecting stronger demand for flexibility and deeper exploration.

Travellers are increasingly structuring trips across multiple cities to maximise both time and value, with popular combinations including:

Tokyo – Osaka – Kyoto (Japan)Seoul – Busan (South Korea)Bangkok – Phuket (Thailand)

These itineraries reflect a growing preference for multi-stop journeys that blend urban experiences with leisure destinations.

Southeast Asia sees fast growth in multi-destination travel

Across Southeast Asia, demand for multi-destination travel is rising steadily, with strong growth across key markets of Thailand: 52%, Malaysia: 40%, and Singapore: 17%, according to Trip.com Group data.

Top outbound destinations across Southeast Asian markets include Japan (Tokyo, Osaka), South Korea (Seoul), China (Shanghai, Beijing), Thailand (Bangkok), Indonesia (Bali).

In other parts of Asia such as Hong Kong SAR, multi-destination travel also grew by over 50% year-on-year, highlighting growing preference for more complex itineraries over traditional single-destination trips, particularly in well-connected urban markets.

In Mainland China, domestic travel remains a strong base, while overseas journeys are increasingly shaped by multi-destination itineraries, with over 40% of outbound trips spanning multiple destinations and continuing to grow.

This suggests that travellers in this region are increasingly combining multiple cities within a single trip, supported by strong regional connectivity.

Japan’s domestic travel momentum on the rise

Japan is also seeing shifts in domestic travel behaviour, even as outbound demand continues to grow.

In Japan, domestic travel is growing rapidly, indicating rising interest in travelling within the country, accounting for one-quarter of all flight bookings, and to cities such as Tokyo, Sapporo and Okinawa.

Intra-Asia travel dominates Labour Day demand

The Labour Day holiday period continues to be driven by regional travel within Asia-Pacific, with travellers favouring destinations that offer ease of access, diverse experiences, and flexible itineraries.

The Group’s data highlights the continued strength of short-haul travel, supported by strong connectivity and shorter flight durations.

More broadly, the way people travel across Asia-Pacific is evolving. Travellers taking a more deliberate approach to how they plan their trips. While cross-border journeys are increasingly shaped by multi-city itineraries, domestic travel remains a strong and steady part of the landscape. Together, these patterns point to a more flexible and value-conscious mindset, as travellers look to make the most of both time and budget.

About Trip.com Group

Trip.com Group is a leading global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of comprehensive travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group has become one of the best-known travel groups in the world, with the mission “to pursue the perfect trip for a better world”. Find out more about Trip.com Group here: group.trip.com.